Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Personalized blood thinners could slash stroke risk

NCT ID NCT06714526

Disease control Sponsor: Sunnybrook Health Sciences Centre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a genetic test can help doctors pick the right blood thinner for people who have had a stroke due to narrowed arteries in the brain. Some people's genes make the common drug clopidogrel less effective, so another drug, ticagrelor, may work better. The study will compare standard care with a genetic testing approach to see which is safer and more practical.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 40 years old, male and female. * TIA or ischemic stroke secondary to symptomatic atherosclerotic stenosis of 30- 99% involving the intracranial ICA or MCA or posterior circulation arteries as evidenced by CT or MR angiography. * Index TIA or ischemic stroke event occurred within past 30 days. * Clinical indication for DAPT for at least 3 months. Exclusion Criteria: * Any contraindication to DAPT. * Any contraindication to use of clopidogrel (Plavix) or ticagrelor (Brilinta), such as pregnancy. A pregnancy test will be performed on all women of child-bearing age prior to enrollment in the study. * Indication for chronic anticoagulation based on guideline recommendations or investigator's judgment (e.g., atrial fibrillation, mechanical heart valve, intracardiac clot, dilated cardiomyopathy, ejection fraction \<30%, etc.). * Intracranial arterial occlusion (i.e. 100% stenosis) responsible for the acute brain ischemia. * Intracranial arterial stenosis secondary to causes other than atherosclerosis. * Extracranial carotid disease with a plan for carotid revascularization. * Intraluminal thrombus. * Unstable subdural hematoma within 12 months of randomization not amenable to embolization. * Previous spontaneous hemorrhagic stroke. * Traumatic brain hemorrhage within 1 month of randomization. * Living in a nursing home or requiring daily nursing care or assistance with activities of daily living. * Intracranial tumor (except meningioma) or any intracranial vascular malformation. * Life expectancy less than 6 months. * Enrolment in another study that would conflict with the current study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intracranial atherosclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

intracranial arteriosclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intracranial atherosclerosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dr. Mark I. Boulos - Sunnybrook Health Sciences Centre

    RECRUITING

    Toronto, Ontario, M4N3M5, Canada

  • University of Calgary

    NOT_YET_RECRUITING

    Calgary, Alberta, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.